Clinical Trial

Intravenous Hydromorphone for the Treatment of Acute Pain

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
To observe the efficacy and safety of hydromorphone in the treatment of acute chest pain, and to explore the potential advantages of hydromorphone for analgesia in patients with acute chest pain, so as to provide more theoretical basis for individualized analgesia and rapid recovery in patients with acute chest pain.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-21.
Trial Details
NCT Number NCT06949059
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborators: Yichang Humanwell Pharmaceutical Co., Ltd., China
Conditions Acute Chest Pain
Enrollment 30 participants
Start Date 2025-01-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-17